OrbiMed’s Kymera Therapeutics KYMR Stock Holding History

OrbiMed’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-100,000	Closed	-$3.23M	–	155
2020 Q3	$3.23M	Buy	+100,000	New	+$3.05M	0.04%	131

Other funds holding KYMR

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DIC

Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed's KYMR Position: Q4 2020 in Review

OrbiMed sold out of Kymera Therapeutics (KYMR) in Q4 2020, closing a stake of 100,000 shares — an estimated $3.23M sold.

OrbiMed first reported a position in KYMR in Q3 2020 and held it in 1 quarter. The position peaked at $3.23M in Q3 2020. 75 funds tracked by Wall St. Rank hold KYMR as of Q4 2020.

OrbiMed reported no remaining Kymera Therapeutics position as of Q4 2020 after selling out during the quarter.
OrbiMed sold 100,000 Kymera Therapeutics shares in Q4 2020, an estimated $3.23M.
OrbiMed first reported a position in Kymera Therapeutics in Q3 2020 and held it in 1 quarter.
OrbiMed's Kymera Therapeutics position peaked at $3.23M in Q3 2020.
75 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.